Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)
March 07 2022 - 8:30AM
Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage
biopharmaceutical company developing disruptive therapeutics for
the treatment of patients with cancer today announced that an
abstract for SBP-101, a proprietary polyamine analogue, has been
accepted for poster presentation at the American Association for
Cancer Research (AACR), which will be held April 8-13, 2022. The
work reflects the Company’s on-going collaboration with Johns
Hopkins University School of Medicine.
Details of the presentation are as follows:
Poster Presentation
- Title: The potential
of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a
polyamine metabolism modulator in ovarian cancer
- Session Category:
Experimental and Molecular TherapeuticsSession Title: Small
Molecule Therapeutic Agents Abstract #: 5488
- Additional meeting
information can be found on the AACR website: Abstracts | AACR
Annual Meeting 2022 | April 8-13, 2022 | New Orleans
- The abstract and
poster will also be available on the Company's website
at https://panbela.com/events-presentations/
once the information has been released by AACR
About SBP-101
SBP-101 is a proprietary polyamine analogue designed to induce
polyamine metabolic inhibition (PMI) by exploiting an observed high
affinity of the compound for pancreatic ductal adenocarcinoma and
other tumors. The molecule has shown signals of tumor growth
inhibition in clinical studies of US and Australian metastatic
pancreatic cancer patients, demonstrating a median overall survival
(OS) of 12.0 months which is not yet final, and an objective
response rate (ORR) of 48%, both exceeding what is seen typically
with the standard of care of gemcitabine + nab-paclitaxel
suggesting potential complementary activity with the existing
FDA-approved standard chemotherapy regimen. In data evaluated from
clinical studies to date, SBP-101 has not shown exacerbation of
bone marrow suppression and peripheral neuropathy, which can be
chemotherapy-related adverse events. Serious visual adverse events
have been evaluated and patients with a history of retinopathy or
at risk of retinal detachment will be excluded from future SBP-101
studies. The safety data and PMI profile observed in the current
Panbela sponsored clinical trial provides support for continued
evaluation of SBP-101 in a randomized clinical trial. For more
information, please
visit https://clinicaltrials.gov/ct2/show/NCT03412799 .
About Panbela
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing disruptive therapeutics for patients with urgent
unmet medical needs. The company’s initial product candidate,
SBP-101, is for the treatment of patients with metastatic
pancreatic ductal adenocarcinoma, the most common type of
pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to
treating patients with pancreatic cancer, ovarian cancer, and
exploring SBP-101’s potential for efficacy in combination with
other agents in other cancer indications. Further information can
be found
at www.panbela.com. Panbela
Therapeutics, Inc. common stock is listed on The Nasdaq Stock
Market LLC under the symbol PBLA.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains “forward-looking
statements,” including within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as: “believe,” “expect,” “feel,” “intend,”
“may,” “plan,” and “scheduled.” Examples of forward-looking
statements include statements we make regarding our intention to
continue to innovate and build our patent portfolio. All statements
other than statements of historical fact are statements that should
be deemed forward-looking statements. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current
beliefs, expectations, and assumptions regarding the future of our
business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and
financial condition may differ materially and adversely from the
forward-looking statements. Therefore, you should not rely on
any of these forward-looking statements. Important factors
that could cause our actual results and financial condition to
differ materially from those indicated in the forward-looking
statements include, among others, the following: (i) our ability
and the combined company’s ability to obtain additional funding to
complete clinical trials; (ii) progress and success of our Phase 1
clinical trial; (iii) the impact of the current COVID-19 pandemic
on our ability to complete monitoring and reporting in our current
clinical trial and procure the active ingredient; (iv) our ability
to demonstrate the safety and effectiveness of our SBP-101 product
candidate (v) our ability to obtain regulatory approvals for our
SBP-101 product candidate in the United States, the European
Union or other international markets; (vi) the market acceptance
and level of future sales of our SBP-101 product candidate; (vii)
the cost and delays in product development that may result from
changes in regulatory oversight applicable to our SBP-101
product candidate; (viii) the rate of progress in establishing
reimbursement arrangements with third-party payors; (ix) the effect
of competing technological and market developments; (x) the costs
involved in filing and prosecuting patent applications and
enforcing or defending patent claims; and (xi) such other factors
as discussed in Part I, Item 1A under the caption “Risk Factors” in
our most recent Annual Report on Form 10-K, any additional risks
presented in our Quarterly Reports on Form 10-Q and our Current
Reports on Form 8-K. Any forward-looking statement made by us in
this press release is based on information currently available to
us and speaks only as of the date on which it is made. We
undertake no obligation to publicly update any forward-looking
statement or reasons why actual results would differ from those
anticipated in any such forward-looking statement, whether
written or oral, whether as a result of new
information, future developments or otherwise.
Contact Information:
Investors: James Carbonara Hayden IR (646)
755-7412 james@haydenir.com
Media: Tammy Groene Panbela Therapeutics,
Inc. (952) 479-1196 IR@panbela.com
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Sep 2023 to Sep 2024